CordenPharma Expands Sterile Injectable Production Capacity

CordenPharma has significantly expanded its manufacturing capacity for sterile injectable drugs. The company announced an increase in its aseptic fill-finish capacity to 500 million sterile injectable units per year.

This expansion aims to meet growing demand and support drug development processes from clinical trials through to commercial production. The investment specifically targets the manufacturing of complex injectable medications.

The company seeks to enhance its supply chain flexibility and accelerate the time-to-market for new pharmaceuticals. The increased capacity allows for the production of various drug molecules within the same facilities.

CordenPharma provides comprehensive services to the pharmaceutical industry, including the development and manufacturing of active pharmaceutical ingredients (APIs) and finished drug products. This expansion reinforces the company's standing in the sector.